You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

IMODIUM A-D Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Imodium A-d, and what generic alternatives are available?

Imodium A-d is a drug marketed by J And J Consumer Inc and is included in three NDAs.

The generic ingredient in IMODIUM A-D is loperamide hydrochloride. There are eleven drug master file entries for this compound. One hundred and three suppliers are listed for this compound. Additional details are available on the loperamide hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Imodium A-d

A generic version of IMODIUM A-D was approved as loperamide hydrochloride by MYLAN on September 18th, 1991.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for IMODIUM A-D?
  • What are the global sales for IMODIUM A-D?
  • What is Average Wholesale Price for IMODIUM A-D?
Summary for IMODIUM A-D
US Patents:0
Applicants:1
NDAs:3
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 117
Clinical Trials: 25
Patent Applications: 3,264
What excipients (inactive ingredients) are in IMODIUM A-D?IMODIUM A-D excipients list
DailyMed Link:IMODIUM A-D at DailyMed
Drug patent expirations by year for IMODIUM A-D
Drug Sales Revenue Trends for IMODIUM A-D

See drug sales revenues for IMODIUM A-D

Recent Clinical Trials for IMODIUM A-D

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
MedSIRPhase 2
Gilead SciencesPhase 2
Naia PharmaceuticalsPhase 1/Phase 2

See all IMODIUM A-D clinical trials

Pharmacology for IMODIUM A-D
Drug ClassOpioid Agonist
Mechanism of ActionOpioid Agonists

US Patents and Regulatory Information for IMODIUM A-D

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
J And J Consumer Inc IMODIUM A-D loperamide hydrochloride SOLUTION;ORAL 019487-001 Mar 1, 1988 OTC Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
J And J Consumer Inc IMODIUM A-D EZ CHEWS loperamide hydrochloride TABLET, CHEWABLE;ORAL 020448-001 Jul 24, 1997 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
J And J Consumer Inc IMODIUM A-D loperamide hydrochloride SUSPENSION;ORAL 019487-002 Jul 8, 2004 OTC Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
J And J Consumer Inc IMODIUM A-D loperamide hydrochloride TABLET;ORAL 019860-001 Nov 22, 1989 OTC Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for IMODIUM A-D

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0428296 SPC/GB98/013 United Kingdom ⤷  Sign Up PRODUCT NAME: LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE; REGISTERED: UK 00242/0314 19970923
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.